Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis

Authors

  • Andrea Cortese Dermatology, Humanitas Research Hospital – IRCCS, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Saverio Pancetti Pathology, Humanitas Research Hospital - IRCCS, Rozzano (MI), Italy
  • Tiziana Pressiani Oncology, Humanitas Research Hospital - IRCCS, Rozzano (MI), Italy
  • Francesco Toso Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Giovanni Fiorillo Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Costanzo Antonio Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
  • Riccardo G. Borroni Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy

Keywords:

sorafenib, acute generalized exanthematous pustulosis, severe cutaneous adverse reaction, tyrosin-kinase inhibitors

References

Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119. DOI: 10.1034/j.1600-0560.2001.028003113.x. PMID: 11168761.

Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996. DOI: 10.1111/j.1365-2133.2007.08156.x. PMID: 17854366.

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. DOI: 10.1038/clpt.1981.154. PMID: 7249508.

Bracarda S, Ruggeri EM, Monti M, et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378-386. DOI: 10.1016/j.critrevonc.2011.08.005. PMID: 21944842.

Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445. DOI: 10.1111/j.1365-2133.2011.10377.x. PMID: 21495998.

Pretel M, Iñarrairaegui M, Lera JM, Aguado L, Idoate MA. Acute generalized exanthematous pustulosis induced by sorafenib. JAMA Dermatol. 2014;150(6):664-666. DOI: 10.1001/jamadermatol.2013.6924. PMID: 24671701.

Alegre-Sánchez A, de Perosanz-Lobo D, Pinilla-Pagnon I, Muñoz-Zato E. Sorafenib-induced Acute Generalized Exanthematous Pustulosis: An Increasing Association? Actas Dermosifiliogr. 2017;108(6):599-601. DOI: 10.1016/j.ad.2016.11.018. PMID: 28262110.

Downloads

Published

2023-04-29

Issue

Vol. 13 No. 2 (2023): 2023 Vol 13, No 2 | April

Section

Research Letter

License

Copyright (c) 2023 Andrea Cortese, Pancetti Saverio, Pressiani Tiziana, Francesco Toso, Giovanni Fiorillo, Costanzo Antonio, Borroni Riccardo G.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Cortese A, Pancetti S, Pressiani T, et al. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis. Dermatol Pract Concept. 2023;13(2):e2023130. doi:10.5826/dpc.1302a130

Share

Crossref
Scopus
Google Scholar
Europe PMC